Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Genfleet (劲方医药) IPO: Trading Update

Genfleet (劲方医药) Pre-IPO: Thoughts on Valuation

GenFleet Therapeutics (劲方医药) Pre-IPO: Leadership in KRAS G12D Target

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

GenFleet Therapeutics / Equity Capital Markets

<ul>
<li>Genfleet, a China-based clinical stage biotech company, launched its IPO to raise at least USD 204 million via a Hong Kong listing.</li>
<li>In our previous note, we have examined the company’s core product and key product and our thoughts on valuation.</li>
<li>In this note, we look at the deal term. We think the valuation provides margin of safety while sentiment is positive.</li>
</ul>


Genfleet, a China-based clinical stage biotech company, launched its IPO to raise at least USD 204 million via a Hong Kong listing.
In our previous note, we have examined the company’s core product and key product and our thoughts on valuation.
In this note, we look at the deal term. We think the valuation provides margin of safety while sentiment is positive.


Genfleet (劲方医药) IPO: Margin of Safety